Supraglottic carcinoma: A retrospective study of 114 patients

J. Shvero*, T. Hadar, E. Yaniv, G. Marshak, R. Feinmesser, K. Segal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


We retrospectively evaluated the management of supraglottic carcinoma at our centre during the last 35 years to determine the preferred mode of treatment. A review of the medical records yielded 114 patients with supraglottic T1 and T2 carcinoma who mere diagnosed and treated in the Departments of Otolaryngology, Head and Neck Surgery, and Oncology between 1959 and 1993. Of these, 47 (41.2%) had T1 carcinoma (stage I) and 67 (58.8%) T2 (stage II). Treatment varied among radiotherapy, surgery, or combined radiotherapy and surgery. Twelve patients underwent elective neck dissection, one of whom (8.3%) was found to have occult metastases. Local failures were noted in 22 patients (11 T1: 11 T2), three of whom also had neck metastases. All except one T2 patient received radiotherapy. Radiotherapy yielded the best survival rates for T1 disease as combined therapy did for T2. Five-year recurrence rates for T1 patients were 35% for those treated by radiotherapy and 42% for chose treated with combined therapy; corresponding figures for T2 patients were 39% and 28%. We suggest that patients with T1 supraglottic carcinoma be managed with radiotherapy and patients with T2 with combined therapy. We believe there is no need for elective neck dissection, especially in T1.

Original languageEnglish
Pages (from-to)289-292
Number of pages4
JournalEuropean Journal of Surgical Oncology
Issue number4
StatePublished - 1997
Externally publishedYes


FundersFunder number
Saul A. Silverman Foundation


    • Laryngeal carcinoma
    • Radiation therapy
    • Supraglottic laryngectomy


    Dive into the research topics of 'Supraglottic carcinoma: A retrospective study of 114 patients'. Together they form a unique fingerprint.

    Cite this